Chemotherapy-induced neutropenia and treatment efficacy in advanced non-small-cell lung cancer: A pooled analysis of three randomised trials

Lancet Oncology

Volumn 6, Issue 9, 2005, Pages 669-677

  Di Maio, Massimo ^a   Gridelli, Cesare ^b,r   Gallo, Ciro ^c   Shepherd, Frances ^d   Piantedosi, Franco Vito ^e   Cigolari, Silvio ^f   Manzione, Luigi ^g   Illiano, Alfonso ^e   Barbera, Santi ^h   Robbiati, Sergio Federico ⁱ   Frontini, Luciano ^j   Piazza, Elena ^k   Ianniello, Giovanni Pietro ^l   Veltri, Enzo ^m   Castiglione, Federico ⁿ   Rosetti, Francesco ^o   Gebbia, Vittorio ^p   Seymour, Lesley ^q   Chiodini, Paolo ^c   Perrone, Francesco ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b S G MOSCATI HOSPITAL   (Italy)

^c SECOND UNIVERSITY OF NAPLES   (Italy)

^d UNIVERSITY OF TORONTO   (Canada)

^e MONALDI HOSPITAL   (Italy)

^f S Giovanni di dio e Ruggi d'Aragona Hospital   (Italy)

^g SAN CARLO HOSPITAL   (Italy)

^h Mariano Santo Hospital   (Italy)

ⁱ Civile Hospital   (Italy)

^j SAN GERARDO HOSPITAL   (Italy)

^k UNIVERSITY OF MILAN   (Italy)

^l Azienda Sanitaria Locale   (Italy)

^m Hospital of Gaeta   (Italy)

ⁿ S Lazzaro Hospital   (Italy)

^o Civil Hospital   (Italy)

^p LA MADDALENA CANCER CENTER   (Italy)

^q QUEEN S UNIVERSITY   (Canada)

^r NATIONAL CANCER INSTITUTE   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; NAVELBINE;

ADULT; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; HUMAN; INTERNATIONAL CLASSIFICATION OF DISEASES; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STATISTICAL ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CARCINOMA, NON-SMALL-CELL LUNG; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; FEMALE; HUMANS; ITALY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEUTROPENIA; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SEVERITY OF ILLNESS INDEX; SURVIVAL RATE;

EID: 24044542973     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(05)70255-2     Document Type: Article

References (26)

1. Non-small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: A meta-analysis using updated data on individual patients from 52 randomised clinical trials BMJ 311 1995 899-909
2. The Elderly Lung cancer Vinorelbine Italian Study group Effects of vinorelbine on quality of life and survival of elderly patients with advanced non small cell lung cancer J Natl Cancer Inst 91 1999 66-72
3. C Delbaldo S Michiels N Syz et al. Benefits of adding a drug to a single-agent or a 2-agent chemotherapy regimen in advanced non-small-cell lung cancer: A meta-analysis JAMA 292 2004 470-484
4. DG Pfister DH Johnson CG Azzoli et al. American Society of Clinical Oncology treatment of unresectable non-small-cell lung cancer guideline: update 2003 J Clin Oncol 22 2004 330-353
5. JH Schiller D Harrington CP Belani et al. Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92-98
6. C Gridelli F Perrone C Gallo et al. for the MILES Investigators Chemotherapy for elderly patients with advanced non-small-cell lung cancer: The Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial J Natl Cancer Inst 95 2003 362-372
7. S Kvinnsland The leucocyte nadir, a predictor of chemotherapy efficacy? Br J Cancer 80 1999 1681
8. H Gurney How to calculate the dose of chemotherapy Br J Cancer 86 2002 1297-1302
9. T Saarto C Blomqvist P Rissanen I Elomaa Haematological toxicity: A marker of adjuvant chemotherapy efficacy in stage II and III breast cancer Br J Cancer 75 1997 301-305
10. P Poikonen T Saarto J Lundin et al. Leucocyte nadir as a marker for chemotherapy efficacy in node-positive breast cancer treated with adjuvant CMF Br J Cancer 80 1999 1763-1766
11. C Mayers T Panzarella IF Tannock Analysis of the prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma Cancer 91 2001 2246-2257
12. DA Cameron C Massie G Kerr RCF Leonard Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer Br J Cancer 89 2003 1837-1842
13. C Gridelli C Gallo FA Shepherd et al. Gemcitabine plus vinorelbine compared to cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non-small-cell lung cancer. A phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada - Clinical Trials Group J Clin Oncol 21 2003 3025-3034
14. AB Miller B Hoogstraten M Staquet A Winkler Reporting results of cancer treatment Cancer 47 1981 207-214
15. EP Cortes JF Holland JJ Wang et al. Amputation and adriamycin in primary osteosarcoma N Engl J Med 221 1974 998-1000
16. JT Carpenter WA Maddox HL Laws et al. Favorable factors in the adjuvant therapy of breast cancer Cancer 50 1982 18-23
17. S Singh W Parulekar N Murray et al. Influence of gender on toxicity and treatment outcome in small cell lung cancer J Clin Oncol 23 2005 850-856
18. H Gurney Dose calculation of anticancer drugs: A review of the current practice and introduction of an alternative J Clin Oncol 14 1996 2590-2611
19. MJ Ratain Body-surface area as a basis for dosing anticancer agents: science, myth, or habit? J Clin Oncol 16 1998 2297-2298
20. M Sawyer MJ Ratain Body surface area as a determinant of pharmacokinetics and drug dosing Investigational New Drugs 19 2001 171-177
21. FE de Jongh L Verweij WJ Loos et al. Body-surface area-based dosing does not increase accuracy of predicting cisplatin exposure J Clin Oncol 19 2001 3733-3739
22. L Nguyen B Tranchand C Puozzo P Variol Population pharmacokinetics model and limited sampling strategy for intravenous vinorelbine derived from phase I clinical trials Br J Clin Pharmacol 53 2002 459-468
23. S Allerheiligen R Johnson B Hatcher et al. Gemcitabine pharmacokinetics are influenced by gender, body surface area, and duration of infusion Proc Am Soc Clin Oncol 13 1994 136
24. J Bergh Tailored chemotherapy to equal toxicity: Is it possible? Recent Results Cancer Res 152 1998 328-340
25. J Bergh T Wiklund B Erikstein et al. Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: A randomised trial. Scandinavian Breast Group 9401 study Lancet 356 2000 1384-1391
26. WE Evans MV Relling JH Rodman et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia N Engl J Med 338 1998 499-550